Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 5/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24798149 | 0.85 | NUDT1 (0.42) | IRAK4NUDT1HDAC1HDAC8HDAC6 | |
| SCHEMBL14880145 | 0.83 | NUDT1 (0.55) | DHFRDCPSFFAR1IRAK4NUDT1 | |
| SCHEMBL15999363 | 0.81 | IRAK4 (0.39) | DHFRDCPSFFAR1IRAK4NUDT1 | |
| SCHEMBL14896631 | 0.78 | FFAR1 (0.39) | DHFRDCPSFFAR1IRAK4NUDT1 | |
| SCHEMBL8277616 | 0.78 | IRAK4 (0.39) | DHFRDCPSFFAR1IRAK4PDE2A | |
| SCHEMBL14897631 | 0.78 | DHFR (0.47) | DHFRDCPSFFAR1IRAK4PDE2A | |
| SCHEMBL14879923 | 0.74 | DHFR (0.52) | DHFRDCPSFFAR1IRAK4NUDT1 | |
| SCHEMBL14230842 | 0.73 | FLT3 (0.40) | DHFRDCPSFFAR1IRAK4FLT3 | |
| SCHEMBL14230841 | 0.73 | FLT3 (0.40) | DHFRDCPSFFAR1IRAK4FLT3 | |
| SCHEMBL15999331 | 0.72 | DHFR (0.44) | DHFRDCPSFFAR1IRAK4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768509-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-20140288052-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2014-09-25 | — | — | US | disclosed |
| US-20140249147-A1 | Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators | GlaxoSmithKline, LLC (US) | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288052-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | DHFR 1318/4885DCPS 2680/4885FFAR1 2531/4885 |
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | DHFR 1318/4885DCPS 2680/4885FFAR1 2531/4885 |
| US-20140249147-A1 | Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | DHFR 1416/4885DCPS 2599/4885FFAR1 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.